Evaluation of Phenobarbital Serum Levels on Clinical Outcomes for the Treatment of Severe Alcohol Withdrawal Syndrome in a Medical Intensive Care Unit

Moqadam S. Rhamatzada, Krislyn A. Schweiger, Paul H. Mayo, Zubair M. Hasan, Mangala Narasimhan, Joanna S. Fishbein, Keith P. Falsetta, Department of Pharmacy Services, Long Island Jewish Medical Center, Northwell Health, New Hyde Park, Division of Pulmonary, Critical Care, and Sleep Medicine, Long Island Jewish Medical Center, Northwell Health, New Hyde Park, Division of Pulmonary, Critical Care, and Sleep Medicine, Northshore University Medical Center, Northwell Health, Medical Intensive Care Unit, Long Island Jewish Medical Center, Northwell Health, New Hyde Park, Critical Care Services, Medical Director of the Acute Lung Injury, VV ECMO Program, Northwell Health, New Hyde Park, Office of Academic Affairs, Northwell Health, New Hyde Park

Journal of Pharmacy Practice

Published online on May 13, 2026

Abstract

Journal of Pharmacy Practice, Ahead of Print.
Background:Optimal phenobarbital serum levels for treating severe alcohol withdrawal syndrome (AWS) remain unclear.Objective:This study evaluated whether phenobarbital serum levels are associated with symptom control in patients with severe AWS ...